Addex Financial Statements From 2010 to 2024

ADXN Stock  USD 20.05  0.91  4.34%   
Addex Therapeutics financial statements provide useful quarterly and yearly information to potential Addex Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Addex Therapeutics financial statements helps investors assess Addex Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Addex Therapeutics' valuation are summarized below:
Gross Profit
1.4 M
Market Capitalization
21.8 M
Enterprise Value Revenue
10.5652
Revenue
1.6 M
Earnings Share
(18.45)
We have found one hundred twenty available fundamental signals for Addex Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Addex Therapeutics' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 20th of April 2024, Market Cap is likely to grow to about 584 M. Also, Enterprise Value is likely to grow to about 554.8 M

Addex Therapeutics Total Revenue

2.82 Million

Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex main balance sheet or income statement drivers, such as Depreciation And Amortization of 290.7 K, Interest Expense of 20.5 K or Total Revenue of 2.8 M, as well as many exotic indicators such as Price To Sales Ratio of 316, Ptb Ratio of 89.6 or Days Sales Outstanding of 32.52. Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Addex Therapeutics Technical models . Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Addex Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.4 M4.6 M17.6 M
Slightly volatile
Short and Long Term Debt Total448 K344.3 K486.2 K
Very volatile
Other Current Liabilities3.1 M2.8 M2.2 M
Pretty Stable
Total Current LiabilitiesM2.9 M3.4 M
Pretty Stable
Total Stockholder Equity1.1 M1.1 M13.6 M
Slightly volatile
Property Plant And Equipment Net335.3 K352.9 K855 K
Slightly volatile
Current Deferred Revenue412.9 K270.2 K293.5 K
Slightly volatile
Accounts Payable913.8 K984.4 KM
Pretty Stable
Cash3.7 M3.9 M15.4 M
Slightly volatile
Non Current Assets Total386.9 K407.3 K1.4 M
Slightly volatile
Non Currrent Assets Other51.6 K54.3 K565.2 K
Slightly volatile
Cash And Short Term Investments3.7 M3.9 M15.4 M
Slightly volatile
Common Stock Total Equity39.7 M37.8 M20.9 M
Slightly volatile
Common Stock Shares Outstanding131.5 M125.2 M31.7 M
Slightly volatile
Liabilities And Stockholders Equity4.4 M4.6 M17.6 M
Slightly volatile
Other Current Assets1.1 BB195.6 M
Slightly volatile
Other Stockholder Equity288.6 M329.9 M268.1 M
Slightly volatile
Total Liabilities4.5 M3.5 M4.1 M
Very volatile
Property Plant And Equipment Gross2.4 M4.7 M1.8 M
Pretty Stable
Total Current AssetsM4.2 M16.2 M
Slightly volatile
Short Term Debt193.4 K274 K133.1 K
Slightly volatile
Common Stock1.8 M1.8 M15 M
Pretty Stable
Non Current Liabilities Total761.6 K603.1 K703.7 K
Slightly volatile
Net Receivables271.7 K151.3 K420.8 K
Slightly volatile
Other Assets66 K48.9 K152.6 K
Slightly volatile
Capital Surpluse297.8 M329.3 M277.1 M
Slightly volatile
Property Plant Equipment275.1 K458.5 K210.9 K
Slightly volatile
Net Invested Capital1.1 M1.1 M7.6 M
Pretty Stable
Net Working Capital1.3 M1.3 MM
Pretty Stable
Capital Stock1.8 M1.8 M25.1 M
Slightly volatile

Addex Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization290.7 K306 K714.2 K
Slightly volatile
Total Revenue2.8 M1.6 MM
Pretty Stable
Other Operating Expenses16.8 M11.9 M14.8 M
Pretty Stable
Research Development2.6 M2.7 M5.5 M
Pretty Stable
Total Operating Expenses15.5 M11.9 M12.8 M
Very volatile
Selling General Administrative4.4 M7.2 M5.2 M
Pretty Stable
Cost Of Revenue17.7 M16.8 M8.7 M
Very volatile
Interest Income65.8 K64 K101.8 K
Slightly volatile
Reconciled Depreciation268.3 K306 K138.8 K
Slightly volatile

Addex Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.2 M2.1 M1.1 M
Slightly volatile
Begin Period Cash Flow6.6 MM18.3 M
Slightly volatile
Depreciation290.7 K306 K691.8 K
Slightly volatile
End Period Cash Flow3.7 M3.9 M15.4 M
Slightly volatile
Issuance Of Capital Stock2.2 M2.4 M25.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3163331.5 K
Pretty Stable
PTB Ratio89.696.4139
Pretty Stable
Days Sales Outstanding32.5234.23091.3 K
Slightly volatile
Book Value Per Share0.120.138.1998
Slightly volatile
Invested Capital0.320.30060.0576
Slightly volatile
Average Payables1.4 M1.4 M944 K
Slightly volatile
Stock Based Compensation To Revenue3.12.982.6689
Very volatile
PB Ratio89.696.4139
Pretty Stable
Payables Turnover10.8310.313.7688
Slightly volatile
Sales General And Administrative To Revenue4.244.466920.5776
Slightly volatile
Research And Ddevelopement To Revenue1.621.70411.3358
Slightly volatile
Cash Per Share0.170.188.1902
Slightly volatile
Days Payables Outstanding34.8136.642.2 K
Pretty Stable
Intangibles To Total Assets0.00230.0030.0034
Very volatile
Net Debt To EBITDA0.340.35532.8777
Very volatile
Current Ratio1.391.46364.483
Pretty Stable
Tangible Book Value Per Share0.120.138.1854
Slightly volatile
Receivables Turnover9.7410.662910.2708
Slightly volatile
Graham Number1.161.2230.0076
Slightly volatile
Shareholders Equity Per Share0.120.138.1998
Slightly volatile
Debt To Equity0.320.30060.0576
Slightly volatile
Average Receivables359.7 K530.6 K325.2 K
Very volatile
Revenue Per Share0.03440.03620.8803
Slightly volatile
Interest Debt Per Share0.01020.01070.0438
Slightly volatile
Debt To Assets0.07790.07420.0205
Slightly volatile
Dividend Yield3.0E-45.0E-42.0E-4
Slightly volatile
Price Book Value Ratio89.696.4139
Pretty Stable
Days Of Payables Outstanding34.8136.642.2 K
Pretty Stable
Ebt Per Ebit0.721.02671.0014
Pretty Stable
Company Equity Multiplier4.264.05242.2777
Pretty Stable
Long Term Debt To Capitalization0.06080.05790.0156
Slightly volatile
Total Debt To Capitalization0.240.23110.047
Slightly volatile
Debt Equity Ratio0.320.30060.0576
Slightly volatile
Quick Ratio1.321.38864.3582
Pretty Stable
Cash Ratio1.271.3364.2466
Pretty Stable
Days Of Sales Outstanding32.5234.23091.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.00091.0133
Slightly volatile
Price To Book Ratio89.696.4139
Pretty Stable
Fixed Asset Turnover4.344.570193.2456
Very volatile
Debt Ratio0.07790.07420.0205
Slightly volatile
Price Sales Ratio3163331.5 K
Pretty Stable
Asset Turnover0.360.34750.1201
Slightly volatile
Price Fair Value89.696.4139
Pretty Stable

Addex Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap584 M473.6 M894.1 M
Slightly volatile

Addex Fundamental Market Drivers

Cash And Short Term Investments3.9 M

Addex Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Addex Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Addex Therapeutics income statement, its balance sheet, and the statement of cash flows. Addex Therapeutics investors use historical funamental indicators, such as Addex Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Addex Therapeutics investors may use each financial statement separately, they are all related. The changes in Addex Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Addex Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Addex Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Addex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue270.2 K412.9 K
Total Revenue1.6 M2.8 M
Cost Of Revenue16.8 M17.7 M
Stock Based Compensation To Revenue 2.98  3.10 
Sales General And Administrative To Revenue 4.47  4.24 
Research And Ddevelopement To Revenue 1.70  1.62 
Capex To Revenue(0)(0)
Revenue Per Share 0.04  0.03 
Ebit Per Revenue(6.37)(6.69)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Addex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Addex Therapeutics' short interest history, or implied volatility extrapolated from Addex Therapeutics options trading.

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Addex Stock

  0.65ELYM Eliem TherapeuticsPairCorr

Moving against Addex Stock

  0.85JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr
  0.69ALKS Alkermes Plc Financial Report 24th of April 2024 PairCorr
  0.68PCRX Pacira Pharmaceuticals Financial Report 1st of May 2024 PairCorr
  0.64PFE Pfizer Inc Report 7th of May 2024 PairCorr
  0.64MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Addex Stock analysis

When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Addex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.45)
Revenue Per Share
2.64
Quarterly Revenue Growth
(0.69)
Return On Assets
(0.99)
Return On Equity
(3.48)
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.